Top-line results from The Medicines Co.'s first pivotal phase III trial of the cholesterol-lowering candidate inclisiran met all primary and secondary efficacy endpoints, with safety "at least as favorable" as in two recent studies, the company said, addressing a top concern for investors tracking the program. Though final results of the study, Orion-11, won't be made public until next week's European Society of Cardiology Congress (ESC) in Paris, excitement about what Evercore ISI analyst Umer Raffat said could be the "first 'vaccine' for cholesterol management," dosed twice-yearly, lifted Medco shares (NASDAQ:MDCO) 13.8% to $39.85 on Monday.